Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Diabetes and Endo
    • Golden drug SGLT2...

    Golden drug SGLT2 Inhibitors may lead to Fournier Gangrene, confirms post marketing review

    Written by Deepanjana Sarkar Published On 2019-05-19T20:20:14+05:30  |  Updated On 13 Aug 2021 2:30 PM IST
    Golden drug SGLT2 Inhibitors may lead to Fournier Gangrene, confirms post marketing review

    The sodium-glucose cotransporter-2 (SGLT2) Inhibitors have been in discussion due to its possible association with Fournier Gangrene (FG). It has been now confirmed that use of SGLT2 Inhibitor is linked to a rare urologic emergency called Fournier Gangrene. A review of spontaneous postmarketing cases published in the Annals of Internal Medicine has reported that the US Food and Drug Administration (FDA) has identified 55 unique cases of FG in patients receiving Sodium-glucose cotransporter-2 (SGLT2) Inhibitor between 1 March 2013 and 31 January 2019.


    Sodium-glucose cotransporter-2 (SGLT2) Inhibitors is a commonly prescribed medicine for the treatment of type-2 diabetes patients. The drug is given to type 2 diabetic patients to control their blood sugar levels. The SGLT2 inhibitors are termed as golden drugs because they have shown an additional overwhelming beneficial effect in lowering the risk of end-stage kidney disease.


    The US Food and Drug Administration had previously made a safety announcement on 20.08.2018 wherein the FDA has affirmed that cases of a rare but serious infection of the genitals and area near the genitals have been reported with this class of drug. Taking a cue from the FDA warning the CDSCO India has also issued safety letter to its state counterparts to direct manufacturers of SGLT2 inhibitors such as Canagliflozin, Dapagliflozin, Empagliflozin, to include a safety warning in the packages.


    Read more: Manufacturers of SGLT2 inhibitor Drugs to have to INCLUDE safety WARNING in package: CDSCO


    The present study was meant to describe and compare reported cases of FG in diabetic adults receiving treatment with Sodium-glucose cotransporter-2 (SGLT2) Inhibitors or other antiglycemic agents. The study reported that 55 unique cases of FG in patients receiving SGLT2 inhibitors between 1 March 2013 and 31 January 2019 identified by the US FDA.


    Please also read-PERSPECTIVE: Diabetes management with SGLT2 inhibitors changing directions- Dr Anoop Misra, Dr Amrita Ghosh

    The key finding of the study are:




    • The patients ranged in age from 33 to 87 years; 39 were men, and 16 were women.

    • Time to onset after initiation of SGLT2-inhibitor therapy ranged from 5 days to 49 months.

    • All patients had surgical debridement and were severely ill.

    • Reported complications included diabetic ketoacidosis, sepsis or septic shock, and acute kidney injury.

    • Eight patients had fecal diversion surgery, 2 patients developed necrotizing fasciitis of a lower extremity that required amputation, and 1 patient required a lower-extremity bypass procedure because of gangrenous toes.

    • Three patients died. For comparison, the FDA identified 19 FG cases associated with other antiglycemic agents between 1984 and 31 January 2019: metformin, insulin glargine, short-acting insulin, sitagliptin plus metformin, and dulaglutide.

    • These patients ranged in age from 42 to 79 years; 12 were men, and 7 were women. Two patients died.


    The authors concluded that FG is a newly identified safety concern in patients receiving Sodium-glucose cotransporter-2 (SGLT2) Inhibitors and advised the physicians prescribing these agents to be aware of this possible complication and have a high index of suspicion to recognize it in its early stages.


    To know more about the study, please click on the link

    DOI: 10.7326/M19-0085
    blood sugarCDSCOCDSCO IndiadiabetesFDAFournier GangreneketoacidosisNecrotizing fasciitissepsisseptic shockSGLT2 inhibitorType-2 diabetes

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Deepanjana Sarkar
    Deepanjana Sarkar
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok